Kamada Ltd. (the "Company") (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the "Ruling") from the Israel Tax Authority (the "ITA") with respect to the cash dividend of $0.25 (approximately NIS 0.77) per share on the Company's ordinary shares (totaling approximately $14.4 million) announced on March 11, 2026 (the "Dividend"), expected to be paid on April 7, 2026 (the "Payment Date"), to shareholders of record at the close of business on March 23, 2026 (the "Record Date").

As a result of the Ruling, shareholders who hold Company shares as of the Record Date that trade such shares on the Nasdaq Stock Market ("Nasdaq Shareholders") and are residents of a country with which Israel has a tax treaty ("Treaty State") may be eligible for a reduced Israeli withholding tax rate (a "Reduced Withholding Tax Rate") on their share of the Dividend (the "Nasdaq Dividend"), in comparison to the generally applicable Israeli withholding tax rate under certain terms and conditions.